Asia-Pacific dry eye syndrome treatment market is projected to register a substantial CAGR in the forecast period of 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Product Type (Emulsions, Lubricant Eye Drops/Solutions, Eye Ointments, Autologous Serum Eye Drops, Nutrition Supplements, Others), Disease Type (Evaporative Dry Eye Syndrome, Aqueous Dry Eye Syndrome), Treatment Type (Lubricating Agents, Tear Stimulators, Artificial Tears, Anti-Inflammatory Drugs, Antibiotic Drugs, Others), End User (Home Healthcare, Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific)
Some of the major factors contributing to the growth of the Asia-Pacific dry eye syndrome treatment market:

? Growing number of generic products
? Due to the rising population, the prevalence rate of eye disease is increasing

Market Players

The key market players for Asia-Pacific dry eye syndrome treatment market are listed below:

? Mitotech, SA
? Johnson & Johnson Services, Inc.
? Sun Pharmaceutical Industries Ltd.
? ALLERGAN
? Novaliq GmbH
? Prestige Consumer Healthcare, Inc.
? Horus Pharma
? Senju Pharmaceutical Co. Ltd.
? VISUfarma
? Akorn, Incorporated
? Bausch & Lomb Incorporated
? Teva Pharmaceutical Industries Ltd.
? Alcon Inc.
? Santen Pharmaceutical Co., Ltd.
? Novartis AG
? Similasan
? Others